SCHEMBL5025872

SCHEMBL5025872

COc1cc(-n2c(S)nc3ccccc3c2=O)c(Cl)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
ALOX12 P18054 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
HPGD P15428 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.48
TP53 P04637 3/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 2/20 0.47
LMNA P02545 1/20 0.46
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPK1 P28482 1/20 0.43
GRM4 Q14833 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30193213 1.00 MEN1 (0.56) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL14978829 0.91 L3MBTL1 (0.49) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL18231290 0.87 HTT (0.56) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL24452828 0.87 MEN1 (0.47) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL20817495 0.86 NPSR1 (0.47) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL30660755 0.86 NPSR1 (0.47) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL24453262 0.86 MEN1 (0.46) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL24453264 0.85 NPSR1 (0.46) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL14010911 0.84 LMNA (0.58) MEN1KMT2AALOX12NPSR1HPGD
SCHEMBL24453266 0.83 NPSR1 (0.44) MEN1KMT2AALOX12NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203497-A1 DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES UNIVERSITE DE STRASBOURG (FR) 2023-06-29 US claimed
US-20210196732-A1 Drug Targets of Delayed Aging and Human Brain Diseases TEXAS TECH UNIVERSITY SYSTEM 2021-07-01 US claimed
EP-3286317-B1 DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY UNIV STRASBOURG (FR) 2021-02-24 EP claimed
US-20190307749-A1 Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease TEXAS TECH UNIVERSITY SYSTEM 2019-10-10 US claimed
WO-2018098484-A1 DRUG TARGETS OF DELAYED AGING AND HUMAN BRAIN DISEASES TEXAS TECH UNIVERSITY SYSTEM (US) 2018-05-31 WO claimed
US-20160264976-A1 DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-09-15 US claimed
WO-2005051974-A2 NOVEL MOLECULES FOR REGULATING CELL DEATH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-06-09 WO claimed
US-20050038051-A1 Novel molecules for regulating cell death NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-17 US claimed
EP-4702130-A1 HYPOXIA-RESISTANT IMMUNE CELLS FOR SUSTAINED PERSISTENCE AND FUNCTIONALITY IN THE HYPOXIC TUMOR MICROENVIRONMENT Universiteit Antwerpen (BE) 2026-03-04 EP disclosed
US-12208108-B2 Drug targets of delayed aging and human brain diseases TEXAS TECH UNIVERSITY SYSTEM (US) 2025-01-28 US disclosed
WO-2024223860-A1 HYPOXIA-RESISTANT IMMUNE CELLS FOR SUSTAINED PERSISTENCE AND FUNCTIONALITY IN THE HYPOXIC TUMOR MICROENVIRONMENT UNIVERSITEIT ANTWERPEN (BE) 2024-10-31 WO disclosed
EP-4397770-A1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PreAnalytiX GmbH (CH) 2024-07-10 EP disclosed
EP-4311546-A1 COMBINATION THERAPY FOR MYOPATHIES Dynacure (FR) 2024-01-31 EP disclosed
EP-3401406-B1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PREANALYTIX GMBH (CH) 2023-11-29 EP disclosed
US-20130045443-A1 POLYMER, RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN TOKYO OHKA KOGYO CO., LTD. (JP) 2013-02-21 US disclosed
US-20080287473-A1 NOVEL MOLECULES FOR REGULATING CELL DEATH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-11-20 US disclosed
US-20080287473-A1 NOVEL MOLECULES FOR REGULATING CELL DEATH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-11-20 US disclosed
US-20080287473-A1 NOVEL MOLECULES FOR REGULATING CELL DEATH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-11-20 US disclosed
WO-2005051974-A2 NOVEL MOLECULES FOR REGULATING CELL DEATH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-06-09 WO disclosed
US-20050038051-A1 Novel molecules for regulating cell death NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287473-A1 NOVEL MOLECULES FOR REGULATING CELL DEATH AIFM1, BAX, HSPE1 MEN1 4201/4885KMT2A 4447/4885ALOX12 3239/4885
US-20190307749-A1 Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease NLN, AIFM1, NDUFAB1 MEN1 3382/4885KMT2A 4480/4885ALOX12 3463/4885
US-12208108-B2 Drug targets of delayed aging and human brain diseases DNM1L, DNM1, DNM2 MEN1 3108/4885KMT2A 2173/4885ALOX12 4248/4885
US-20210196732-A1 Drug Targets of Delayed Aging and Human Brain Diseases DNM1L, DNM1, DNM2 MEN1 3108/4885KMT2A 2173/4885ALOX12 4248/4885
US-20050038051-A1 Novel molecules for regulating cell death AIFM1, BAX, HSPE1 MEN1 4201/4885KMT2A 4447/4885ALOX12 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.